$DD

JPMorgan Downgrades DuPont de Nemours to Neutral From Overweight $145 Price Target

JPMorgan downgraded DuPont de Nemours to 'Neutral' from 'Overweight' and set a $145 price target. The company's stock is currently at $130.56, up 0.43% on the day but down 0.05% year-to-date. This move may impact investor sentiment and trading activity.

Original reporting
Published Oct 12, 2026, 4:32 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 12, 2026, 4:47 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$DD
Bearish
medium confidence
Mentioned
$DD
Relevance
6/10
AlphAI data visualization · based on marketscreener.com
Decision brief

The 30-second read

$DDBearishMed
01

Why it matters

A downgrade from Overweight to Neutral typically reduces expected upside and can shift flows away from the stock, particularly for systematic strategies that track sell-side ratings.

02

Market read

This is a direct sell-side stance change on DD with an explicit new price target, useful for short-term positioning and relative-value decisions.

03

What to watch

The body includes no thesis details behind the downgrade, so traders should verify whether the change is driven by valuation, margin outlook, PFAS/legal overhang, or estimate revisions not shown here.

Relevance 6/10Novelty 4/10Timing: as of the analyst note publication date, for same-day positioning and near-term sentiment

Background

The text frames the update as a JPMorgan rating change for DuPont de Nemours, but does not include the underlying rationale or new company-specific data.

Company-level read

Ticker impact

$DDBearishMedium confidence
Context

JPMorgan downgraded DuPont de Nemours to Neutral from Overweight and set a $145 price target, signaling a valuation and outlook reset for DD.

Expected impact

Likely downside bias as the market reprices the downgrade and target, especially for investors tracking JPMorgan’s stance.

Evidence & confidence

The article’s only concrete, company-specific content is the rating change and the stated $145 target; no additional fundamentals or new events are provided.

Market effects

Materials and industrials sentiment can soften modestly when a large-name chemical/industrial is downgraded, but the article provides no sector-wide catalyst.

No clear regional spillover is described beyond the US-listed analyst action.

Limited global relevance because the disclosure is a single-company rating change with no cross-border transaction details.

Counterpoint

The downgrade may be more about valuation than deteriorating fundamentals; if DD’s underlying earnings power is unchanged, the stock could stabilize after the initial reaction.

Key entities

  • DuPont de Nemours

    Subject of the JPMorgan downgrade to Neutral and $145 price target.

  • JPMorgan

    Brokerage issuing the downgrade and price target.

Related articles

$DDMed

DD Downgraded by JP Morgan -- Price Target Lowered to $145

JP Morgan downgraded DuPont de Nemours (DD) to Neutral, lowering its price target from $172 to $145. GuruFocus estimates DD is 83.5% overvalued, with a GF Value of $70.97 vs. current price of $130.24. DD's P/E (TTM) is 309.35x, far above its 5-year median of 7.91x. Analysts cite concerns about growth and profitability.

$DDHigh

JPMorgan downgrades DuPont stock rating on recovery outlook

JPMorgan downgraded DuPont (NYSE:DD) to Neutral from Overweight, lowering its price target to $145 from $172. The stock trades at $132.48, considered undervalued. DuPont reported Q2 2026 earnings, beating estimates with $1.88 EPS and $1.82B revenue. BMO Capital reiterated its Outperform rating, maintaining a $186 price target.

$DDMed

Attorney General Todd Rokita leads multistate coalition to stop DuPont shell game, hold companies accountable for PFAS contamination

Attorney General Todd Rokita led a 16-state lawsuit against DuPont (EIDP), Corteva, and Vylor, alleging a transfer of assets to avoid PFAS contamination liabilities. The suit seeks to freeze assets and block dividends or buybacks. Rokita claims the companies moved valuable assets to Vylor, leaving liabilities with DuPont. The hearing is set for October 2, 2026.

$DDLow

Judge says 3M, DuPont, and Honeywell must face Connecticut firefighters' PFAS claims

A U.S. judge ruled that 3M, DuPont, Honeywell, and others must face claims from Connecticut firefighters over PFAS exposure in protective gear. The lawsuit alleges the gear, containing 3M's Scotchlite and DuPont's Kevlar, increased cancer risks. The judge allowed the case to proceed, permitting damages and medical monitoring claims. The companies argue the gear served its protective function. PFAS makers face broader scrutiny, with prior settlements totaling over $11 billion.